New tenants choose Fabege in the Drabanten quarter

Fabege has signed two lease agreements in central Stockholm, totalling approximately 1,275 sqm, with pharmaceutical company Chiesi Pharma and accounting firm Kungsbron Borevision in the Drabanten quarter at Kungsbroplan 3.

Drabanten 3, Kungsbroplan 3, Kungsholmen

The building was constructed in 1907 and designed by architect Fredrik Falkenberg. It has five entrances, with Chiesi Pharma leasing 840 sqm at Kungsbroplan 3A and Kungsbron Borevision leasing 435 sqm at Kungsbro Strand 31.

The tenants will move into their new premises in May and September 2027, respectively, and both lease agreements have a term of five years.

“We are really looking forward to moving into our new premises in the Drabanten quarter. Chiesi has grown in recent years, and as our business continues to develop, we need more space. Creating an attractive and inspiring workplace where our employees can thrive, collaborate and grow is important to us. The new, larger premises and central location provide excellent conditions for this,” says Olav Fromm, Managing Director, Chiesi Nordics.

“As our company name suggests, we feel very much at home on Kungsholmen, with its excellent transport links and nearby walking routes. Kungsbron Borevision has experienced strong growth in recent years, and we have now finally found premises that will allow us to continue expanding. Our ambition is to create a warm and welcoming workplace with a family atmosphere, somewhere we enjoy spending time together and genuinely look forward to coming to work each morning,” says Andreas Holman, CEO, Kungsbron Borevision.

Fabege's property portfolio in central Stockholm accounts for approximately 37 per cent of the company's total property value and consists primarily of office properties and workplaces, complemented by residential properties, hotels, shops and restaurants.

Created: 05 November 2026

read also

Stockholm

Stockholm likes to call itself “the Capital of Scandinavia”. When it comes to the office market, it’s no exaggeration.
Read more